Biomednewsbreaks - Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin As Chief Financial Officer

(MENAFN- Investor Brand Network) Annovis Bio (NYSE: ANVS) , a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced the appointment of Mark Guerin, CPA, CMA, CFM, as Chief Financial Officer to help guide the Company as its lead drug candidate, buntanetap, advances through late-stage trials. Guerin previously served as CFO of Onconova Therapeutics, now Traws Pharma (NASDAQ: TRAW), where he oversaw multiple financings and a merger that formed the new entity. His earlier roles include senior finance positions at Cardiokine, Barrier Therapeutics, and Coopers & Lybrand. Guerin said he is eager to support Annovis as it works to replicate buntanetap's early success in registrational studies and deliver solutions for patients with Alzheimer's and Parkinson's disease.

To view the full press release, visit

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit and follow us on LinkedIn , YouTube , and X .

NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN25092025000224011066ID1110111907